Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

X-chromosome role in SEx-dependent Lymphoma Evolution and Clonal Trajectories

Objective

Despite recent advances, we still lack a coherent framework explaining how genetic lesions, aberrant cell fate decisions and host factors intersect to drive immunological neoplasms (lymphoma). We have uncovered an entirely new dimension: gender bias as a fundamental driver of lymphoma evolution. Our data show that a newly discovered type of lymphoma called BN2-DLBCL, defined by SPEN and NOTCH2 truncations, is specifically highly aggressive in women and rooted in the biology of aged/autoimmune B cells (AiBCs); cells classically linked to autoimmunity. This suggests a central role for female gender effects where immune dysfunction, chronic inflammation, and failed X-chromosome inactivation (XCI) converge. We hypothesize that SPEN loss destabilizes XCI, unleashing bi-allelic expression of X-encoded TLR7/IRAK1 and hyperactive inflammatory signaling; NOTCH2 mutations reroute these signals into AiBC fate, creating lymphoma precursors that expand clonally, exhaust T cells, and reshape immune microenvironments. The result is a uniquely female-biased malignant trajectory, overturning conventional lymphoma paradigms. With X-SeLECT (X-chromosome role in SEx-dependent Lymphoma Evolution and Clonal Trajectories) we will systematically dissect this biology. Using single-cell multi-omics, spatial proteogenomics, real-time dynamics (3-photon microscopy), and lineage tracing, we will reconstruct the stepwise clonal evolution of AiBCs into BN2-DLBCL and define the gender-specific immune circuits that sustain them. Finally, we will exploit these insights to uncover sex-specific vulnerabilities, testing how TLR/IRAK blockade, statins, and immune checkpoint synergy can dismantle these malignant networks. This project will deliver a paradigm shift: establishing AiBCs as the first bona fide lymphoma-initiating and repopulating cells, demonstrating that gender and X-linked immunity are central to cancer biology, and charting the way toward precision, sex-informed therapies in lymphoma.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-ADG

See all projects funded under this call

Host institution

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Net EU contribution
€ 3 499 123,75
Address
CARRETERA DE CAN RUTI CAMI DE LES ESCOLES S/N
08916 Badalona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)